KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Halozyme Therapeutics (HALO) Shares Outstanding (Diluted Average) (2016 - 2025)

Historic Shares Outstanding (Diluted Average) for Halozyme Therapeutics (HALO) over the last 14 years, with Q3 2025 value amounting to $124.4 million.

  • Halozyme Therapeutics' Shares Outstanding (Diluted Average) fell 436.86% to $124.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $124.4 million, marking a year-over-year decrease of 436.86%. This contributed to the annual value of $129.4 million for FY2024, which is 355.67% down from last year.
  • As of Q3 2025, Halozyme Therapeutics' Shares Outstanding (Diluted Average) stood at $124.4 million, which was down 436.86% from $125.5 million recorded in Q2 2025.
  • Halozyme Therapeutics' Shares Outstanding (Diluted Average)'s 5-year high stood at $148.5 million during Q1 2021, with a 5-year trough of $124.4 million in Q3 2025.
  • Its 5-year average for Shares Outstanding (Diluted Average) is $136.5 million, with a median of $135.8 million in 2023.
  • Per our database at Business Quant, Halozyme Therapeutics' Shares Outstanding (Diluted Average) soared by 827.64% in 2021 and then tumbled by 653.59% in 2024.
  • Quarter analysis of 5 years shows Halozyme Therapeutics' Shares Outstanding (Diluted Average) stood at $146.8 million in 2021, then decreased by 4.22% to $140.6 million in 2022, then dropped by 4.56% to $134.2 million in 2023, then dropped by 3.56% to $129.4 million in 2024, then decreased by 3.84% to $124.4 million in 2025.
  • Its Shares Outstanding (Diluted Average) stands at $124.4 million for Q3 2025, versus $125.5 million for Q2 2025 and $126.6 million for Q1 2025.